Concepts (184)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Renal Dialysis | 15 | 2019 | 261 | 6.100 |
Why?
|
| Kidney Failure, Chronic | 16 | 2019 | 519 | 4.810 |
Why?
|
| Catheterization, Central Venous | 4 | 2017 | 60 | 1.980 |
Why?
|
| African Americans | 13 | 2019 | 1373 | 1.870 |
Why?
|
| Arteriovenous Shunt, Surgical | 3 | 2017 | 45 | 1.700 |
Why?
|
| Diabetes Mellitus, Type 2 | 6 | 2018 | 1383 | 1.520 |
Why?
|
| Apolipoproteins | 10 | 2019 | 196 | 1.350 |
Why?
|
| Albuminuria | 5 | 2015 | 177 | 1.280 |
Why?
|
| Lipoproteins, HDL | 9 | 2016 | 247 | 1.170 |
Why?
|
| Uric Acid | 2 | 2018 | 24 | 1.090 |
Why?
|
| Renal Insufficiency, Chronic | 3 | 2018 | 271 | 0.980 |
Why?
|
| Kidney Diseases | 8 | 2019 | 239 | 0.930 |
Why?
|
| Catheters, Indwelling | 2 | 2014 | 40 | 0.880 |
Why?
|
| Humans | 39 | 2019 | 29220 | 0.780 |
Why?
|
| Fluid Therapy | 1 | 2019 | 27 | 0.710 |
Why?
|
| Middle Aged | 24 | 2019 | 10872 | 0.710 |
Why?
|
| Male | 27 | 2019 | 17876 | 0.690 |
Why?
|
| Catheter-Related Infections | 2 | 2019 | 10 | 0.670 |
Why?
|
| Genetic Predisposition to Disease | 9 | 2015 | 836 | 0.660 |
Why?
|
| Psoas Muscles | 1 | 2018 | 19 | 0.630 |
Why?
|
| Female | 25 | 2019 | 18241 | 0.630 |
Why?
|
| Patient Selection | 1 | 2019 | 257 | 0.620 |
Why?
|
| Hyperuricemia | 2 | 2018 | 12 | 0.610 |
Why?
|
| Heparin | 1 | 2017 | 75 | 0.580 |
Why?
|
| Aged | 15 | 2019 | 9515 | 0.550 |
Why?
|
| Anticoagulants | 1 | 2017 | 122 | 0.550 |
Why?
|
| Molecular Motor Proteins | 3 | 2012 | 58 | 0.550 |
Why?
|
| Blood Vessel Prosthesis Implantation | 1 | 2016 | 68 | 0.550 |
Why?
|
| Myosin Heavy Chains | 3 | 2012 | 86 | 0.550 |
Why?
|
| Kidney Glomerulus | 2 | 2014 | 30 | 0.530 |
Why?
|
| Polymorphism, Single Nucleotide | 8 | 2013 | 1079 | 0.490 |
Why?
|
| Hypertension | 2 | 2012 | 913 | 0.480 |
Why?
|
| Diabetes Complications | 1 | 2015 | 171 | 0.470 |
Why?
|
| Receptors, Notch | 2 | 2010 | 16 | 0.460 |
Why?
|
| Risk Factors | 11 | 2017 | 3550 | 0.460 |
Why?
|
| Gout | 1 | 2012 | 14 | 0.440 |
Why?
|
| Diabetic Nephropathies | 2 | 2013 | 195 | 0.440 |
Why?
|
| Chemokine CCL2 | 1 | 2012 | 47 | 0.430 |
Why?
|
| Serum Albumin | 1 | 2012 | 53 | 0.430 |
Why?
|
| Anti-Bacterial Agents | 2 | 2011 | 285 | 0.420 |
Why?
|
| Proteinuria | 1 | 2012 | 57 | 0.410 |
Why?
|
| Minocycline | 1 | 2011 | 11 | 0.410 |
Why?
|
| Environmental Exposure | 1 | 2012 | 87 | 0.400 |
Why?
|
| Cognition Disorders | 1 | 2015 | 390 | 0.400 |
Why?
|
| Length of Stay | 1 | 2012 | 294 | 0.400 |
Why?
|
| Diabetic Angiopathies | 1 | 2012 | 137 | 0.400 |
Why?
|
| Bacteremia | 1 | 2011 | 53 | 0.390 |
Why?
|
| Kidney | 3 | 2014 | 486 | 0.390 |
Why?
|
| Fatty Acids | 1 | 2010 | 93 | 0.370 |
Why?
|
| Aged, 80 and over | 5 | 2019 | 3728 | 0.360 |
Why?
|
| Prognosis | 5 | 2018 | 1363 | 0.360 |
Why?
|
| Hospitalization | 1 | 2012 | 418 | 0.350 |
Why?
|
| Polymorphism, Genetic | 1 | 2010 | 196 | 0.340 |
Why?
|
| DNA | 1 | 2010 | 204 | 0.340 |
Why?
|
| Risk Assessment | 4 | 2019 | 1313 | 0.330 |
Why?
|
| Glomerular Filtration Rate | 6 | 2015 | 287 | 0.320 |
Why?
|
| Brain | 1 | 2015 | 930 | 0.310 |
Why?
|
| Acetyl-CoA Carboxylase | 3 | 2013 | 21 | 0.310 |
Why?
|
| Adult | 14 | 2019 | 8468 | 0.290 |
Why?
|
| Signal Transduction | 1 | 2010 | 667 | 0.280 |
Why?
|
| Tumor Virus Infections | 2 | 2018 | 20 | 0.280 |
Why?
|
| Cardiovascular Diseases | 2 | 2015 | 1019 | 0.280 |
Why?
|
| Polyomavirus Infections | 2 | 2018 | 21 | 0.280 |
Why?
|
| Kidney Transplantation | 1 | 2010 | 353 | 0.270 |
Why?
|
| Genetic Variation | 3 | 2015 | 251 | 0.250 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 2 | 2013 | 72 | 0.220 |
Why?
|
| Prevalence | 3 | 2016 | 907 | 0.220 |
Why?
|
| Incidence | 2 | 2016 | 1123 | 0.210 |
Why?
|
| Age Factors | 2 | 2016 | 1110 | 0.210 |
Why?
|
| Time Factors | 3 | 2017 | 2003 | 0.210 |
Why?
|
| Ultrafiltration | 2 | 2019 | 9 | 0.200 |
Why?
|
| Membrane Proteins | 2 | 2013 | 256 | 0.200 |
Why?
|
| Prospective Studies | 3 | 2017 | 2027 | 0.200 |
Why?
|
| Quality of Life | 2 | 2016 | 820 | 0.190 |
Why?
|
| Retrospective Studies | 3 | 2018 | 3122 | 0.190 |
Why?
|
| United States | 3 | 2015 | 3648 | 0.180 |
Why?
|
| Cohort Studies | 3 | 2012 | 1695 | 0.180 |
Why?
|
| Treatment Outcome | 2 | 2017 | 3108 | 0.170 |
Why?
|
| Genome-Wide Association Study | 2 | 2012 | 543 | 0.170 |
Why?
|
| Survival Rate | 2 | 2018 | 795 | 0.170 |
Why?
|
| Knowledge | 1 | 2018 | 15 | 0.170 |
Why?
|
| Weight Gain | 1 | 2019 | 109 | 0.170 |
Why?
|
| Forecasting | 1 | 2019 | 133 | 0.170 |
Why?
|
| Follow-Up Studies | 3 | 2019 | 2114 | 0.160 |
Why?
|
| Peritoneal Dialysis | 1 | 2018 | 22 | 0.160 |
Why?
|
| Outpatients | 1 | 2018 | 49 | 0.160 |
Why?
|
| Cisplatin | 1 | 2018 | 69 | 0.160 |
Why?
|
| Health Status Indicators | 1 | 2018 | 67 | 0.160 |
Why?
|
| JC Virus | 2 | 2018 | 23 | 0.160 |
Why?
|
| Longitudinal Studies | 2 | 2017 | 725 | 0.160 |
Why?
|
| African Continental Ancestry Group | 3 | 2016 | 350 | 0.150 |
Why?
|
| Kidney Function Tests | 2 | 2015 | 102 | 0.150 |
Why?
|
| Mitochondrial Diseases | 1 | 2016 | 11 | 0.150 |
Why?
|
| Survival Analysis | 1 | 2018 | 440 | 0.150 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2018 | 142 | 0.150 |
Why?
|
| Head and Neck Neoplasms | 1 | 2018 | 117 | 0.140 |
Why?
|
| Body Composition | 1 | 2018 | 365 | 0.140 |
Why?
|
| Linear Models | 2 | 2014 | 427 | 0.140 |
Why?
|
| RNA, Messenger | 2 | 2014 | 514 | 0.130 |
Why?
|
| Young Adult | 4 | 2018 | 2413 | 0.130 |
Why?
|
| Multivariate Analysis | 2 | 2014 | 638 | 0.130 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2015 | 60 | 0.130 |
Why?
|
| Hepatocytes | 1 | 2015 | 74 | 0.130 |
Why?
|
| Mesangial Cells | 1 | 2014 | 9 | 0.130 |
Why?
|
| Comorbidity | 1 | 2016 | 546 | 0.130 |
Why?
|
| Kidney Tubules, Proximal | 1 | 2014 | 39 | 0.120 |
Why?
|
| Genotype | 4 | 2019 | 735 | 0.120 |
Why?
|
| Autoantigens | 1 | 2013 | 16 | 0.120 |
Why?
|
| Cross-Sectional Studies | 1 | 2018 | 1366 | 0.120 |
Why?
|
| Glomerulonephritis | 1 | 2013 | 21 | 0.120 |
Why?
|
| Podocytes | 2 | 2014 | 20 | 0.120 |
Why?
|
| Neuropsychological Tests | 1 | 2015 | 379 | 0.120 |
Why?
|
| Liver Neoplasms | 1 | 2015 | 162 | 0.120 |
Why?
|
| Disease Progression | 2 | 2019 | 572 | 0.120 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2018 | 871 | 0.110 |
Why?
|
| European Continental Ancestry Group | 2 | 2015 | 1131 | 0.110 |
Why?
|
| North Carolina | 2 | 2014 | 1425 | 0.110 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2013 | 83 | 0.110 |
Why?
|
| Neoplasm Proteins | 1 | 2013 | 141 | 0.110 |
Why?
|
| Proportional Hazards Models | 1 | 2014 | 710 | 0.100 |
Why?
|
| Family Health | 1 | 2012 | 78 | 0.100 |
Why?
|
| Metabolism | 1 | 2011 | 7 | 0.100 |
Why?
|
| Treatment Failure | 1 | 2012 | 159 | 0.100 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2012 | 134 | 0.100 |
Why?
|
| Adolescent | 3 | 2014 | 3265 | 0.100 |
Why?
|
| Genome, Human | 1 | 2011 | 129 | 0.100 |
Why?
|
| Graft Rejection | 1 | 2011 | 149 | 0.090 |
Why?
|
| Thienamycins | 1 | 2010 | 1 | 0.090 |
Why?
|
| Predictive Value of Tests | 1 | 2012 | 788 | 0.090 |
Why?
|
| Lupus Nephritis | 1 | 2010 | 30 | 0.090 |
Why?
|
| Glomerulosclerosis, Focal Segmental | 1 | 2010 | 36 | 0.090 |
Why?
|
| Oxidation-Reduction | 1 | 2010 | 250 | 0.090 |
Why?
|
| Genetic Association Studies | 3 | 2015 | 148 | 0.090 |
Why?
|
| Body Mass Index | 1 | 2013 | 867 | 0.090 |
Why?
|
| Critical Illness | 1 | 2010 | 87 | 0.090 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2015 | 1219 | 0.090 |
Why?
|
| Intensive Care Units | 1 | 2010 | 118 | 0.090 |
Why?
|
| Immunohistochemistry | 1 | 2010 | 519 | 0.080 |
Why?
|
| Gene Frequency | 3 | 2013 | 225 | 0.080 |
Why?
|
| Obesity | 1 | 2013 | 1068 | 0.070 |
Why?
|
| Case-Control Studies | 2 | 2018 | 860 | 0.060 |
Why?
|
| Cells, Cultured | 2 | 2016 | 800 | 0.060 |
Why?
|
| Chi-Square Distribution | 2 | 2013 | 293 | 0.050 |
Why?
|
| Phenotype | 2 | 2013 | 629 | 0.050 |
Why?
|
| Adipose Tissue | 2 | 2013 | 327 | 0.040 |
Why?
|
| Mice | 2 | 2015 | 2372 | 0.040 |
Why?
|
| Clinical Trials as Topic | 1 | 2019 | 298 | 0.040 |
Why?
|
| Animals | 3 | 2015 | 7302 | 0.040 |
Why?
|
| Proteasome Endopeptidase Complex | 1 | 2015 | 18 | 0.030 |
Why?
|
| Proteomics | 1 | 2015 | 92 | 0.030 |
Why?
|
| Autophagy | 1 | 2015 | 53 | 0.030 |
Why?
|
| Amino Acid Sequence | 1 | 2015 | 280 | 0.030 |
Why?
|
| Molecular Sequence Data | 1 | 2015 | 350 | 0.030 |
Why?
|
| Microscopy, Fluorescence | 1 | 2014 | 81 | 0.030 |
Why?
|
| Bone Morphogenetic Protein 4 | 1 | 2013 | 13 | 0.030 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2015 | 249 | 0.030 |
Why?
|
| Gene Expression Regulation | 1 | 2016 | 481 | 0.030 |
Why?
|
| Epistasis, Genetic | 1 | 2013 | 44 | 0.030 |
Why?
|
| Epithelial Cells | 1 | 2014 | 138 | 0.030 |
Why?
|
| Cystatin C | 1 | 2013 | 28 | 0.030 |
Why?
|
| Nonlinear Dynamics | 1 | 2013 | 52 | 0.030 |
Why?
|
| Biopsy | 1 | 2014 | 241 | 0.030 |
Why?
|
| DNA, Viral | 1 | 2013 | 39 | 0.030 |
Why?
|
| Cell Line | 1 | 2014 | 450 | 0.030 |
Why?
|
| Antineoplastic Agents | 1 | 2018 | 546 | 0.030 |
Why?
|
| Nephrectomy | 1 | 2014 | 114 | 0.030 |
Why?
|
| Cell Line, Tumor | 1 | 2015 | 681 | 0.030 |
Why?
|
| Demography | 1 | 2013 | 104 | 0.030 |
Why?
|
| Risk | 1 | 2013 | 290 | 0.030 |
Why?
|
| Indians, North American | 1 | 2013 | 108 | 0.030 |
Why?
|
| Heredity | 1 | 2012 | 12 | 0.030 |
Why?
|
| Pedigree | 1 | 2012 | 133 | 0.030 |
Why?
|
| Triglycerides | 1 | 2013 | 214 | 0.030 |
Why?
|
| Mice, Knockout | 1 | 2013 | 425 | 0.030 |
Why?
|
| Polymerase Chain Reaction | 1 | 2011 | 172 | 0.020 |
Why?
|
| Rats | 1 | 2015 | 1604 | 0.020 |
Why?
|
| Gene Expression | 1 | 2011 | 332 | 0.020 |
Why?
|
| Regional Blood Flow | 1 | 2010 | 82 | 0.020 |
Why?
|
| Haplotypes | 1 | 2010 | 220 | 0.020 |
Why?
|
| Liver | 1 | 2013 | 464 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 2012 | 864 | 0.020 |
Why?
|
| Insulin Resistance | 1 | 2011 | 449 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2010 | 641 | 0.020 |
Why?
|
| Muscle, Skeletal | 1 | 2011 | 494 | 0.020 |
Why?
|